160 related articles for article (PubMed ID: 21702053)
1. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.
Gréen H; Khan MS; Jakobsen-Falk I; Åvall-Lundqvist E; Peterson C
J Pharm Sci; 2011 Oct; 100(10):4205-9. PubMed ID: 21702053
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.
Hu L; Lv QL; Guo Y; Cheng L; Wu NY; Qin CZ; Zhou HH
J Clin Pharmacol; 2016 Mar; 56(3):349-54. PubMed ID: 26179145
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
4. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Lee MY; Apellániz-Ruiz M; Johansson I; Vikingsson S; Bergmann TK; Brøsen K; Green H; Rodríguez-Antona C; Ingelman-Sundberg M
Pharmacogenomics; 2015; 16(9):929-37. PubMed ID: 26115084
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
Tsukada C; Saito T; Maekawa M; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2015 Oct; 30(5):366-73. PubMed ID: 26427316
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.
Yamaguchi H; Hishinuma T; Endo N; Tsukamoto H; Kishikawa Y; Sato M; Murai Y; Hiratsuka M; Ito K; Okamura C; Yaegashi N; Suzuki N; Tomioka Y; Goto J
Int J Gynecol Cancer; 2006; 16(3):979-85. PubMed ID: 16803472
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
Nakajima M; Fujiki Y; Kyo S; Kanaya T; Nakamura M; Maida Y; Tanaka M; Inoue M; Yokoi T
J Clin Pharmacol; 2005 Jun; 45(6):674-82. PubMed ID: 15901749
[TBL] [Abstract][Full Text] [Related]
9. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
[TBL] [Abstract][Full Text] [Related]
10. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
11. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.
Bergmann TK; Brasch-Andersen C; Gréen H; Mirza MR; Skougaard K; Wihl J; Keldsen N; Damkier P; Peterson C; Vach W; Brøsen K
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):199-204. PubMed ID: 21955855
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Leskelä S; Jara C; Leandro-García LJ; Martínez A; García-Donas J; Hernando S; Hurtado A; Vicario JC; Montero-Conde C; Landa I; López-Jiménez E; Cascón A; Milne RL; Robledo M; Rodríguez-Antona C
Pharmacogenomics J; 2011 Apr; 11(2):121-9. PubMed ID: 20212519
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population.
Adehin A; Bolaji OO; Kennedy MA
Drug Metab Pharmacokinet; 2017 Jun; 32(3):189-191. PubMed ID: 28427759
[TBL] [Abstract][Full Text] [Related]
14. Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers.
de Castro CL; da Costa Junior LC; Lourenço LV; Seba KS; da Silva TSL; Vianna-Jorge R
Arch Gynecol Obstet; 2019 Aug; 300(2):395-407. PubMed ID: 31123858
[TBL] [Abstract][Full Text] [Related]
15. Interethnic differences of cytochrome P450 gene polymorphisms may influence outcome of taxane therapy in Roma and Hungarian populations.
Szalai R; Ganczer A; Magyari L; Matyas P; Bene J; Melegh B
Drug Metab Pharmacokinet; 2015 Dec; 30(6):453-6. PubMed ID: 26507668
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.
Bergmann TK; Brasch-Andersen C; Gréen H; Mirza M; Pedersen RS; Nielsen F; Skougaard K; Wihl J; Keldsen N; Damkier P; Friberg LE; Peterson C; Vach W; Karlsson MO; Brosen K
Pharmacogenomics J; 2011 Apr; 11(2):113-20. PubMed ID: 20368717
[TBL] [Abstract][Full Text] [Related]
17. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.
Taniguchi R; Kumai T; Matsumoto N; Watanabe M; Kamio K; Suzuki S; Kobayashi S
J Pharmacol Sci; 2005 Jan; 97(1):83-90. PubMed ID: 15655291
[TBL] [Abstract][Full Text] [Related]
18. ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.
Björn N; Jakobsen Falk I; Vergote I; Gréen H
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):277-287. PubMed ID: 29504705
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.
García-Martín E; Pizarro RM; Martínez C; Gutierrez-Martín Y; Pérez G; Jover R; Agúndez JA
Pharmacogenomics; 2006 Jun; 7(4):575-85. PubMed ID: 16753005
[TBL] [Abstract][Full Text] [Related]
20. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
Kim JJ; Park JY; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
Acta Obstet Gynecol Scand; 2010 May; 89(5):623-8. PubMed ID: 20423275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
